Provectus Biopharmaceuticals Inc. (OTCQB:PVCT) said this week that its board of directors voted unanimously to terminate CEO and chief operating officer Peter Culpepper, after an internal investigation revealed that Culpepper violated the company’s expense account reimbursement policy.
The Knoxville, Tenn.-based company said it has established a search committee and is actively seeking a new CEO. In the meantime, Provectus president Timothy Scott will serve as interim CEO.
Get the full story at our sister site, Drug Delivery Business News.
The post Provectus axes CEO Culpepper for expense account violations appeared first on MassDevice.
from MassDevice http://ift.tt/2iMNGoT
Cap comentari:
Publica un comentari a l'entrada